Omica Biomed is actively seeking to join or create partnerships within EU cooperation projects, aiming to leverage our expertise in genetic testing and AI-driven diagnostics to contribute significantly to the advancement of healthcare and veterinary medicine across Europe. Our dedication to innovation in the detection of cancer and rare diseases places us in a unique position to collaborate on projects that align with EU objectives for improving patient outcomes, promoting research and development, and integrating cutting-edge technologies into the medical and veterinary fields.

By partnering with like-minded organizations, research institutions, and industry leaders within the EU framework, we aim to enhance the scope and impact of our diagnostic solutions. Our contributions would not only include our state-of-the-art liquid biopsy tests and genetic panels for cancer detection but also our advanced OmiCareAI platform, which exemplifies the integration of clinical, imaging, and genomic data for improved diagnostic accuracy.

Omica Biomed is committed to fostering collaborations that align with the EU's health innovation goals, particularly those that encourage cross-sectoral and interdisciplinary research, and the development of AI and genomic technologies. We believe that through EU cooperation projects, we can collectively advance the frontiers of medicine, offering novel solutions to pressing health challenges and ultimately, improving the quality of life for people and animals across the continent.

---

 Health Care

 Child Care

 Biotechnology

 Innovation & Research

 Medical Biotechnology

 Artificial Intelligence